Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT05170555
Overview
Renal Cell Carcinoma (RCC) is the second most common tumor in urology. Considering its origination from kidney, an organ with intense physiological uptake and excretion of 68Ga-PSMA, this study aims to evaluate the uptake of 68Ga-PSMA in RCC compared to 18F-FDG in the same patients, and assess the feasibility of 177Lu-EB-PSMA-617 treatment in patients with the advanced RCC.
Phase
N/A
Contacts
Zhaohui Zhu, MD
13611093752@163.com
86-13611093752
Guochang Wang, MD
guochang1007@163.com
86-18516822732
ClinicalTrials.gov
NCT05170555Help us improve your experience